Moderator: Kimberly Sciarretta, PhD

HHS/ASPR/BARDA DRIVe Solving Sepsis Program Manager

Kimberly Sciarretta, PhD is the Solving Sepsis Program Manager within the Division of Research Innovation and Ventures (DRIVe), Biomedical Advanced Research and Development Authority (BARDA), part of the Assistant Secretary for Preparedness and Response (ASPR), within the United States Department of Health and Human Services (HHS).  Previously Dr. Sciarretta was a Project Officer within the BARDA CBRN Division, and prior to that, was a technical consultant to multiple US Government Agencies.  Dr. Sciarretta was one of the inaugural members of DRIVe and is leading efforts towards improving patient outcomes for sepsis through strategic interagency activities and critical technology investments with external partners.  Dr. Sciarretta received her PhD from the University of Chicago in Molecular Genetics and Cell Biology.  Her expertise broadly spans medical countermeasure development, biochemistry, synthetic biology, advanced manufacturing and chemical and biological defense technologies. 

Klaudyne Hong, PhD

Chief Executive Officer, Peach IntelliHealth

Klaudyne Hong, PhD, is CEO of Peach IntelliHealth, an AI healthcare company. She became intrigued with AI predictive analytics while watching the movie “Minority Report”. A decade later, while fly fishing, she had an epiphany about creating a new type of Machine Learning technology that could be used by healthcare professionals to predict adverse medical events in patients and prevent them. Peach was formed soon after. Prior to Peach, Dr Hong was a pharma executive at Johnson & Johnson and Schering AG, leading teams in stem cells, gene therapy, vaccine, and oncology. Her technology, publication, and patent portfolio includes research and development in Alzheimer’s, cancer, cardiovascular disease, infectious disease, multiple sclerosis, Parkinson’s, stroke, and spinal cord injury. Dr Hong received her PhD from the Massachusetts Institute of Technology and her MA and BA from California State University Fresno. She works in New York and Singapore.

Rajesh Krishnamurthy, PhD

Chief Technology Officer, 3iDx

Dr. Krishnamurthy has over 20 years of experience in developing therapeutic products and diagnostics. He has overseen the development of over 50 products at different stages of development including two billion dollar drugs - Kadcyla® (breast cancer) and Tanzeum® (diabetes). Prior to starting 3i, he was the Director of Pharmaceutical Development at Zyngenia, Senior Director of Analytical & Pharmaceutical Sciences at ImmunoGen, and Associate Director of Pharmaceutical Sciences at Human Genome Sciences (a subsidiary of GSK).

Robert Quinn

Chief Executive Officer & Co-founder, Patch'd Medical

Robert is the CEO and Co-founder of Patchd Medical. Robert started his career studying both Biomedical Science majoring in Neuroscience and Mechatronic Engineering. During his time studying, he worked in a number of labs conducting research on the cerebellum to working with silicon retinas which sparked his intense interest in the intersection of engineering and science. After graduating Robert then briefly worked in corporate strategy before realizing his true passion was to become an entrepreneur to help solve Sepsis, a condition which had nearly taken his life. With his co-founder Wei-Jien, they started Patchd and within 12 months they were part of the prestigious Y Combinator accelerator. Together they work to use deep learning and off the shelf wearables to help predict the onset of this devastating condition.

Michael Feldschuh

President and CEO, Daxor Corporation

Michael Feldschuh has held the position of president and CEO of Daxor Corporation since December 2015. Prior to this, he served as a member of the Board of Directors before joining Daxor’s executive team in December of 2014. Michael has over 25 years of experience in the medical field and on Wall Street. He served as a managing director and portfolio manager for Morgan Stanley for six years and a managing director of Millennium Partners for eight years in addition to leading his own hedge fund, Aristarc Capital, from 2009 to 2013. Michael began his career at D.E. Shaw & Co. in New York, where he worked with Jeffery Bezos prior to Bezos’s founding of Amazon. Michael earned his bachelor’s degree in pre-medical studies at Columbia College, Columbia University in 1991. Michael’s interests include photography and travel.